Literature DB >> 20922433

Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome.

Anne Marie Sbrocchi1, Frank Rauch, MaryAnn Matzinger, Janusz Feber, Leanne M Ward.   

Abstract

Glucocorticoids (GCs) are associated with fragility fractures in children with various chronic illnesses. The impact of GCs on bone health in children with nephrotic syndrome (NS) is less well understood. Here we report skeletal findings in a 10-year-old boy with steroid-sensitive NS who presented with back pain due to vertebral fractures 5 years after NS diagnosis. Spine radiographs showed a Genant grade 2 fracture at T7 and a grade 1 fracture at T8. Dual-energy X-ray absorptiometry (DXA) revealed a lumbar spine areal bone mineral density (BMD) Z-score of -0.5 and a total body areal BMD Z-score of -0.4. Quantitative transiliac bone histomorphometry revealed low trabecular bone volume and cortical width but no osteomalacia. Our findings show the potential for significant bone morbidity due to osteoporosis in steroid-sensitive NS treated with intermittent GC therapy and emphasize that vertebral fractures may be an underrecognized complication. Furthermore, our report highlights that vertebral fractures can be associated with normal spine areal BMD in this context, suggesting that DXA-based, anteroposterior areal BMD should not be relied upon exclusively for assessing bone health and disease in children with steroid-sensitive NS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922433     DOI: 10.1007/s00467-010-1652-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

1.  Normative data for iliac bone histomorphometry in growing children.

Authors:  F H Glorieux; R Travers; A Taylor; J R Bowen; F Rauch; M Norman; A M Parfitt
Journal:  Bone       Date:  2000-02       Impact factor: 4.398

2.  Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).

Authors:  R J Hogg; R J Portman; D Milliner; K V Lemley; A Eddy; J Ingelfinger
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

Review 3.  Bone histomorphometry in glucocorticoid-induced osteoporosis.

Authors:  D W Dempster
Journal:  J Bone Miner Res       Date:  1989-04       Impact factor: 6.741

4.  Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome.

Authors:  Mustafa Bak; Erkin Serdaroglu; Rengin Guclu
Journal:  Pediatr Nephrol       Date:  2005-12-29       Impact factor: 3.714

5.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version.

Authors:  Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

6.  Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.

Authors:  Philip D Acott; Jaime A Wong; Bianca A Lang; John F S Crocker
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

7.  Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults.

Authors:  I M van der Sluis; M A J de Ridder; A M Boot; E P Krenning; S M P F de Muinck Keizer-Schrama
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

8.  Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.

Authors:  Jacqueline Halton; Isabelle Gaboury; Ronald Grant; Nathalie Alos; Elizabeth A Cummings; Maryann Matzinger; Nazih Shenouda; Brian Lentle; Sharon Abish; Stephanie Atkinson; Elizabeth Cairney; David Dix; Sara Israels; David Stephure; Beverly Wilson; John Hay; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

9.  Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome.

Authors:  Rachel J Wetzsteon; Justine Shults; Babette S Zemel; Pooja U Gupta; Jon M Burnham; Rita M Herskovitz; Krista M Howard; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2009-03       Impact factor: 6.741

10.  Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

Authors:  N F Peel; D J Moore; N A Barrington; D E Bax; R Eastell
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

View more
  6 in total

1.  Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.

Authors:  J Feber; I Gaboury; A Ni; N Alos; S Arora; L Bell; T Blydt-Hansen; C Clarson; G Filler; J Hay; D Hebert; B Lentle; M Matzinger; J Midgley; D Moher; M Pinsk; F Rauch; C Rodd; N Shenouda; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2011-04-15       Impact factor: 4.507

2.  Approach to the child with fractures.

Authors:  Alison M Boyce; Rachel I Gafni
Journal:  J Clin Endocrinol Metab       Date:  2011-07       Impact factor: 5.958

Review 3.  Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.

Authors:  Monica Grover; Laura K Bachrach
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

4.  Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder.

Authors:  Rachel M Holden; Reem A Mustafa; R Todd Alexander; Marisa Battistella; Micheli U Bevilacqua; Greg Knoll; Fabrice Mac-Way; Martina Reslerova; Ron Wald; Philip D Acott; Patrick Feltmate; Allan Grill; Kailash K Jindal; Meena Karsanji; Bryce A Kiberd; Sara Mahdavi; Kailee McCarron; Amber O Molnar; Maury Pinsk; Celia Rodd; Steven D Soroka; Amanda J Vinson; Deborah Zimmerman; Catherine M Clase
Journal:  Can J Kidney Health Dis       Date:  2020-08-04

5.  Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.

Authors:  V Phan; T Blydt-Hansen; J Feber; N Alos; S Arora; S Atkinson; L Bell; C Clarson; R Couch; E A Cummings; G Filler; R M Grant; J Grimmer; D Hebert; B Lentle; J Ma; M Matzinger; J Midgley; M Pinsk; C Rodd; N Shenouda; R Stein; D Stephure; S Taback; K Williams; F Rauch; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2013-08-16       Impact factor: 4.507

6.  Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease.

Authors:  Gia J Oh; Anne Waldo; Francisco Paez-Cruz; Patrick E Gipson; Anne Pesenson; David T Selewski; Elaine S Kamil; Susan F Massengill; Richard A Lafayette; Meg Modes; Sharon G Adler; Hailey Desmond; Richard Eikstadt; Samara Attalla; Zubin J Modi; Jonathan P Troost; Debbie S Gipson
Journal:  Kidney Int Rep       Date:  2019-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.